Menu Search
Equities

Cue Biopharma Inc

CUE:NAQ

Cue Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.70
  • Today's Change-0.17 / -9.09%
  • Shares traded569.10k
  • 1 Year change-26.41%
  • Beta1.7713
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cue Biopharma Inc grew revenues 340.88% from 1.25m to 5.49m while net income improved from a loss of 53.01m to a smaller loss of 50.73m.
Gross margin--
Net profit margin-566.02%
Operating margin-582.23%
Return on assets-81.32%
Return on equity-138.87%
Return on investment-113.52%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Cue Biopharma Inc fell by 3.10m. However, Cash Flow from Investing totalled 25.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 39.96m for operations while cash generated from financing totalled 11.86m.
Cash flow per share-0.963
Price/Cash flow per share--
Book value per share0.4445
Tangible book value per share0.4445
More ▼

Balance sheet in USDView more

Cue Biopharma Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.43% of the market capitalization can be attributed to its 48.51m and debt could be paid in full if management chose.
Current ratio2.06
Quick ratio--
Total debt/total equity0.289
Total debt/total capital0.2242
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.